Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 294
- Registration Number
- NCT05489848
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT05489211
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 632
- Registration Number
- NCT05487391
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai. China, Shanghai, China
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 62
- Registration Number
- NCT05451043
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 172
- Registration Number
- NCT05433597
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
- Conditions
- Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Serous AdenocarcinomaPrimary Peritoneal Endometrioid AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaStage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 45
- Registration Number
- NCT05415709
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 43
- Registration Number
- NCT05410197
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- D3 Bio (Wuxi) Co., Ltd
- Target Recruit Count
- 392
- Registration Number
- NCT05410145
- Locations
- 🇪🇸
D3 Bio Investigative Site, Valencia, Spain
PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05406856
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Netherlands
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Taofeek Owonikoko
- Target Recruit Count
- 50
- Registration Number
- NCT05403723
- Locations
- 🇺🇸
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.